Go to Noxopharm website
Pharmorage
  • Home
  • About Us
    • About Pharmorage
    • About Noxopharm
    • About Hudson Institute of Medical Research
    • Team
  • Technologies
    • Technologies
    • mRNA Technology
    • Autoimmune Disease
  • Publications
    • Publications
  • Contact
    • Contact Us

  • NOX ASX Announcements
  • Media
  • Other Company News
  • Upcoming Events

Recent Posts

  • Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors.
  • Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2′-O-methyl gapmer oligonucleotides
  • Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists
  • Inhibition of STING Signaling with Flavonoid Compounds
  • Characterization of 2’-O-methyl oligonucleotides that potently inhibit cGAS and TLR9 DNA sensing

Categories

  • Conference presentations and posters
  • Media
  • Peer-reviewed journal articles
  • Publications

Cancer drug investigated as anti-inflammatory for lethal conditions including COVID-19

1 April 2020 by Pharmorage
Read More
Page:
  • 1


PHARMORAGE PTY LIMITED
ACN 641 047 403

Quick Links

Contact Us

Email: info@pharmorage.com
Phone: +61 459 022 445

Address:
BIO101 Financial Advisory PTY LTD
Suite 201, 697 Burke Road
Melbourne – Camberwell
VIC 3124

Stay in Touch

Which of the following group do you best fit?

 

Quick Links

Contact Us

Email: info@pharmorage.com
Phone: +61 459 022 445

Address:
BIO101 Financial Advisory PTY LTD
Suite 201, 697 Burke Road
Melbourne – Camberwell
VIC 3124

Perth:
T: +61 8 9429 8881
45 Ventnor Avenue
West Perth, WA 6005

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Pharmorage
Site Map Privacy Search
Site by